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InvasionMicroRNAs play important roles in the development and progression of non-small cell lung cancer
(NSCLC). miR-16 functions as a tumor-suppressor and is inhibited in several malignancies. Herein,
we validated that miR-16 is downregulated in NSCLC tissue samples and cell lines. Ectopic expres-
sion of miR-16 signiﬁcantly inhibited cell proliferation and colony formation. Moreover, miR-16
suppressed cell migration and invasion in NSCLC cells. Hepatoma-derived growth factor (HDGF)
was found to be a direct target of miR-16 in NSCLC cell lines. Rescue experiments showed that the
suppressive effect of miR-16 on cell proliferation, colony formation, migration, and invasion is
partially mediated by inhibiting HDGF expression. This study indicates that miR-16 might be
associated with NSCLC progression, and suggests an essential role for miR-16 in NSCLC.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Lung cancer, which results from uncontrolled proliferation of
cells in the lung, is one of the most common human cancers which
have etiologies of both genetic and environmental origins [1]. Most
lung cancers are carcinomas, arising from epithelial cells, and non-
small cell lung cancer (NSCLC) comprises over 80% of newly diag-
nosed lung cancer cases, and over 70% of NSCLC patients have ad-
vanced disorders. Although recent advances had been developed in
surgery and chemotherapy, the 5-year survival rate of NSCLC is still
only 16% [2]. Lung carcinogenesis is a multistep process, and sys-
tematic analyses of expression levels of both oncogenes and tumor
suppressors involved in the pathogenesis of lung cancer have been
performed, and numerous genes have been identiﬁed to be essen-
tial during carcinogenesis [3–5]. However, the underlying mecha-
nisms of NSCLC remain poorly understood. Therefore, a better
understanding of the detailed mechanisms might be helpful to ﬁnd
new therapeutic targets and strategies for the treatment of NSCLC.
MicroRNAs (miRNAs), which are small and non-coding RNAs,
bind to the complimentary recognition sequences in the 30-
untranslated region (30-UTR) of target mRNA, resulting in transla-
tional inhibition or target mRNA degradation [6]. miRNAs playessential roles in a variety of biological and pathological processes,
including cell proliferation, migration, invasion, apoptosis, and
metastasis [7]. The roles of miRNAs in NSCLC have been widely
studied, and critical regulators of miRNA biogenesis, Dicer, DGCR8,
and Drosha, have been reported to be disrupted in lung cancer
[8,9]. miRNA microarrays studies have identiﬁed many miRNAs
aberrantly expressed in lung cancer [10]. Among them, miR-16
was substantially decreased [11]. miR-16, which is located at chro-
mosome 13q14, is a well-known tumor suppressor miRNA in
multiple human cancers [12]. However, the detailed role of miR-
16 in NSCLC is still poorly understood.
In the present study, we validated that miR-16 was signiﬁcantly
decreased and overexpression of miR-16 signiﬁcantly inhibited the
growth and motility of NSCLC cells. Furthermore, we found that
miR-16 directly targeted HDGF, a potential oncogene.
2. Materials and methods
2.1. Tissue samples, cell lines and transfection
A total of 20 NSCLC tissue samples and matched non-tumor
normal tissue samples were surgically obtained in our department.
Informed consent was taken from all subjects and this work was
approved by the Ethics Committee of Huazhong University of
Science and Technology. Three NSCLC cell lines, A549, Calu3, and
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purchased from ATCC. Cells were grown in RPMI-1640 media con-
taining 10% fetal bovine serum (FBS) at 37 C wih 5% CO2. Cells
were transfected using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA, USA) in Opti-MEM medium (Invitrogen, Carlsbad, CA, USA).
Cells were incubated for 48 h prior to harvesting.
2.2. RNA extraction and quantitative real time PCR (qRT-PCR)
Total RNA was extracted by TRIzol Reagent (Invitrogen, Carls-
bad, CA, USA). SYBR Premix Ex Taq (Takara, Tokyo, Japan) was
used to detect gene expression on ABI Stepone plus (Applied
Biosystems, Foster City, CA, USA). miRNA was extracted using
All-in-one microRNA extraction kit (GeneCopoeia, Carlsbad, CA,
USA). Primers for HDGF: sense, 50-ATCAACAGCCAACAAATACC-30
and anti-sense, 50-TTCTTATCACCGTCACCCT-30. Primers for GAPDH:
sense, 50-AACGGATTTGGTCGTATTG-30, and anti-sense, 50-
GGAAGATGGTGATGGGATT-30. Primers for miR-16 and U6 were
purchased from GeneCopoeia (Carlsbad, CA, USA). The expression
of HDGF was normalized with GAPDH, and the expression of
miR-16 was normalized with U6.
2.3. Plasmids
miR-16 mimic/inhibitor and the corresponding controls were
obtained from RiboBio (Guangzhou, China). pcDNA3-HDGF was
generated by using the following primers: sense, 50-
GGGGTACCTCCTTGGCAAGACAGTAGCT-30 and anti-sense, 50-
CCCTCGAGAAACATTGGTGGCTACAGG-30. The PCR fragment was
inserted into pcDNA3.0 within KpnI and XhoI restriction sites
(Invitrogen, Carlsbad, CA, USA). The 30-UTR of HDGF mRNA was
ampliﬁed from human cDNA using the following primers: sense,
50-CCCTCGAGGGGTGACGGTGATAAGAA-30 and anti-sense, 50-
TTGCGGCCGCGACAGCAGCAGGAACAGG-30. The PCR fragment was
inserted into psiCHECK2 vector within XhoI and NotI restriction
sites (Promega, Madison, WI, USA). Mutation in the miR-16 bind-
ing-sites of HDGF was performed using whole-plasmid ampliﬁca-
tion in the seed region of miR-16 (NEB, Ipswich, Canada).
2.4. MTT cell proliferation assay
Cell proliferation was determined by MTT cell proliferation
assay kit (Roche Applied Science, Foster City, CA, USA). Cells were
seeded in 96-well plates with a density of 4  103 cells/per well.
48 h after treatment, cells were incubated with MTT diluted in
culture medium for 1 h. Then, 100 ll of dimethyl sulfoxide (DMSO)
was added to each well, and the optical density at 570 nm was
measured under a microtiter plate reader.
2.5. Colony formation assay
Twenty four hour after treatment, 500 cells were seeded in a
fresh 6-well plate and maintained in RPMI-1640 medium contain-
ing 10% FBS for 2 weeks. Colonies were ﬁxed and stained with 0.1%
crystal violet for 15 min. Colony numbers were quantiﬁed by Alpha
Innotech imaging software (San Leandro, CA, USA), and percentage
colony formation was analyzed by adjusting control cells to 100.
2.6. Cell migration and invasion assays
For migration assays, 24 h after transfection, 5  104 cells in
serum-free medium were added into the upper chamber of an
insert (8-lm pore size, Millipore, Billerica, MA, USA). For invasion
assays, 1  105 cells in serum-free medium were placed into the
upper chamber of an insert coated with Matrigel (Sigma–Aldrich,
St. Louis, MO USA). Medium containing 10% FBS were added tothe lower chamber as a chemoattractant. After 24 h of incubation,
cells remaining on the upper membrane were removed, whereas
cells which had migrated or invaded to the lower membrane were
stained with 0.1% crystal violet, imaged, and counted using a
microscope (Olympus, Tokyo, Japan). Experiments were performed
independently three times.
2.7. Luciferase reporter assays
A549 cells were co-transfected with wild type HDGF 30-UTR
(WT) or the mutated 30-UTR (Mut) and miR-16 mimic or the
control mimic (miR-NC). Forty eight hour after transfection, cells
were collected and luciferase activity was analyzed using a dual-
luciferase reporter assay system (Promega, Wisconsin, WI, USA).
2.8. Western blotting
Treated cells were washed twice with PBS and proteins were
extracted with SDS lysis buffer (Beyotime, Shanghai, China), and
seperated by 10% SDS–PAGE gel. Protein samples were transferred
to polyvinylidene diﬂuoride (PVDF) membrane (Millipore, Billerica,
MA, USA), and were probed with primary antibodies against HDGF
(Abcam, Cambridge, UK) or GAPDH (Abcam, Cambridge, UK). Mem-
branes were incubated at 4 C overnight, followed by incubation
with AP-conjugated secondary antibodies and detected by ECL.
2.9. Statistical analysis
Two-tail Student’s t-test and One-way ANOVA were performed
to analyze the data using SPSS 12.0. P < 0.05 was considered statis-
tically signiﬁcant.
3. Results
3.1. miR-16 was down-regulated in NSCLC tissues and cell lines
Expression of miR-16 in 20 NSCLC patient tissues and matched
non-tumor normal tissue samples was detected by qRT-PCR. miR-
16 was signiﬁcantly down-regulated in NSCLC patient tissues com-
pared with adjacent normal tissues (Fig. 1A). Similarly, expression
of miR-16 in three NSCLC cell lines, A549, Calu3, and H129 was
signiﬁcantly decreased compared with that in 16HBE cells
(Fig. 1B).
3.2. miR-16 inhibited NSCLC cell growth in vitro
To examine the role of miR-16 in NSCLC cell growth, A549 and
Calu3 cells were transfected with miR-16 mimic or miR-NC. Over-
expression of miR-16 signiﬁcantly inhibited the growth of A549
and Calu3 cells (Fig. 2A). Accordingly, miR-16 overexpression
signiﬁcantly inhibited colony formation in both NSCLC cell lines
(Fig. 2B).
3.3. miR-16 suppressed NSCLC cell migration and invasion
To investigate the effect of miR-16 on the motility of NSCLC
cells, miR-16 or miR-NC was transfected into A549 and Calu3 cells
and migration and invasion assays were performed. miR-16 signif-
icantly suppressed the migration and invasion abilities of NSCLC
cells (Fig. 3A, B).
3.4. HDGF was a direct target of miR-16
To explore the function of miR-16 in NSCLC, we used TargetScan
6.2 to screen the target gene of miR-16. HDGF was predicted to be a
Fig. 1. miR-16 was down-regulated in NSCLC tissues and cell lines. (A) Expression of miR-16 in 20 NSCLC tissues and matched non-tumor normal tissue samples was detected
by qRT-PCR. (B) Expression of miR-16 in three NSCLC cell lines, A549, Calu3, and H1299, and human bronchial epithelial cell line (16HBE) was detected by qRT-PCR.
Expression of miR-16 was normalized with U6. ⁄P < 0.05, ⁄⁄P < 0.01 compared with the control.
Fig. 2. miR-16 inhibited NSCLC cell growth in vitro. (A) The percentage cell proliferation of A549 and Calu3 cells transfected with miR-16 or miR-NC was detected by MTT
assay. (B) The percentage colony formation for A549 and Calu3 cells transfected with miR-16 or miR-NC was calculated. Data were drawn from three independent
experiments. ⁄P < 0.05, ⁄⁄P < 0.01 compared with the control.
Fig. 3. miR-16 suppressed NSCLC cell migration and invasion. (A) In vitro migration assay of A549 and Calu3 cells transfected with miR-16 or miR-NC. (B) In vitro invasion
assay of A549 and Calu3 cells transfected with miR-16 or miR-NC. Data represented three independent experiments. ⁄⁄P < 0.01compared with the control.
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NSCLC. Luciferase activity assay showed that miR-16 signiﬁcantly
inhibited the luciferase activity of the WT 30-UTR but not that of
Mut 30-UTR of HDGF in A549 cells (Fig. 4B). Furthermore, overex-
pression of miR-16 signiﬁcantly suppressed HDGF mRNA and
protein levels (Fig. 4C and D).
3.5. miR-16 inhibited NSCLC cell growth and motility by targeting
HDGF
Further experiments were performed to explore whether
overexpression of HDGF could attenuate the suppressive effect ofmiR-16. MTT assay (Fig. 5A), in vitro cell migration and invasion
(Fig. 5B and C) all showed that supplement of HDGF by pcDNA3-
HDGF could signiﬁcantly attenuate the suppressive effect of miR-
16. The effect of HDGF plasmid was conﬁrmed by qRT-PCR
(Fig. 5D).
4. Discussion
In this study, we studied the expression of miR-16 in NSCLC pa-
tients and cell lines. We found that the expression levels of miR-16
were signiﬁcantly decreased in NSCLC tissues. We also found that
the ectopic expression of miR-16 signiﬁcantly suppressed the
Fig. 4. HDGF was a direct target of miR-16. (A) The potential miR-16 binding sites of HDGF 30-UTR and the mutated sequences. (B) A549 cells were co-transfected with miR-
16 or miR-NC with WT or Mut HDGF 30-UTR. Luciferase activity was detected. (C) Expression of HDGF mRNA was detected by qRT-PCR in cells transfected with miR-16 or
miR-NC. (D) Protein level was detected by Western blotting in A549 cells transfected with miR-16 or miR-NC. GAPDH was used as an internal control. Data were drawn from
three independent experiments. ⁄P < 0.05 compared with the control.
Fig. 5. miR-16 inhibited NSCLC cell growth and motility by targeting HDGF. (A) A549 cells were co-transfected with miR-16 and pcDNA3-HDGF or the vector. MTT assay was
used to detect proliferation. (B) In vitro migration assay of A549 cells co-transfected with miR-16 and pcDNA3-HDGF or the vector. (C) In vitro invasion assay of A549 cells co-
transfected with miR-16 and pcDNA3-HDGF or the vector. Data were drawn from three independent experiments. ⁄P < 0.05, ⁄⁄P < 0.01 compared with control. #P < 0.05,
##P < 0.01 compared with miR-16 group.
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16 remarkably inhibited the migration and invasion of NSCLC cell
lines. By using luciferase activity assay and Western blotting, we
found that HDGF was a direct target of miR-16. Overexpression
of miR-16 suppressed cell growth and motility, whereas overex-
pression of HDGF antagonized this effect. Our data illustrate the
possible role of miR-16 and HDGF in the pathogenesis of NSCLC.
Numerous miRNAs have been found to be decreased in NSCLC
and many of them played essential roles in the regulation of onco-
genesis of NSCLC. For instance, Decreased miR-148a was found to
be associated with lymph node metastasis and poor clinical
outcomes, which acted as a suppressor of tumor metastasis in
NSCLC by target DNA (cytosine-5)-methyltransferase 1 (DNMT1)[13]. Our previous study found that miR-149 was down-regulated
in NSCLC, and it inhibited epithelial-to-mesenchymal transition
process of A549 cells by targeting Forkhead box M1 (FOXM1) [9].
Down-regulation of miR-181b was thought to be a potential prog-
nostic marker of NSCLC. Low miR-181b expression was found to be
tightly correlated with larger tumor size, positive lymph node
metastasis, and higher p-TNM stage of NSCLC patients [14]. miR-
449a, decreased in NSCLC, inhibited migration and invasion by tar-
geting c-Met [15]. miR-16 has been reported to be decreased and to
serve as a tumor suppressor in numerous cancer types. miR-16
inhibited colorectal cancer cell growth in vitro by suppressing
the p53/survivin signaling pathway [16]. miR-16 has been also
found to inhibit osteosarcoma cell proliferation by targeting
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2-ERK1/2 pathway [17]. miR-16 induced apoptosis of rat activated
pancreatic stellate cells by inhibiting Bcl-2 expression in vitro [18].
miR-16 was down-regulated in NSCLC as well [11]. Herein we
demonstrated that HDGF was a direct target of miR-16 in NSCLC
cells and miR-16 acted as a tumor suppressor partially by inhibit-
ing HDGF in NSCLC.
HDGF was highly expressed in different cancers and its expres-
sion was correlated with aggressive biological capabilities of can-
cer cells including proliferation and angiogenesis [19,20].
Knockdown of HDGF inhibited growth, colony formation, vessel
formation in NSCLC tumors, which suggested that HDGF might
be involved in the pathogenesis of NSCLC [21]. Our results showed
that miR-16 inhibited growth, colony formation, migration and
invasion by targeting HDGF in NSCLC cells. These data indicated
that down-regulation of miR-16 in NSCLC might promote growth
and motility through the elevation of HDGF.
In conclusion, this study showed that miR-16 was down-regu-
lated in NSCLC tissues and cell lines, and ectopic expression of
miR-16 suppressed cell proliferation and colony formation
in vitro. HDGF was identiﬁed as a target of miR-16 in NSCLC, and
overexpression of HDGF partially attenuated the suppressive effect
of miR-16, indicating that miR-16 might be a useful marker and a
potential therapeutic target for the treatment of NSCLC.
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